Pfizer CEO Albert Bourla said the company is reassessing its planned investments in Germany amid policy proposals aimed at reducing drug spending. Reuters reported Bourla raised concerns in a letter to Chancellor Friedrich Merz, arguing the reforms could undermine long-term pharma investment predictability. Germany’s proposal targets savings of 16.3 billion euros in 2027, including 1.9 billion euros from drug-spending measures such as higher markdowns on product list prices to health insurers. The plan has also been criticized by other executives, including Novartis leadership. Separately, Reuters reporting noted other large drugmakers are already adjusting investment commitments in response to the same policy uncertainty. The reported actions raise the stakes for how quickly new medicines can be launched into a historically fast-reimbursing market. For biotech partners and suppliers, Germany’s pricing trajectory can influence tender timing, clinical trial enrollment economics, and the attractiveness of European commercialization strategies.